• Chlorpromazine: A Translational Research Lever

  2026-09-11

  Chlorpromazine is more than a historical antipsychotic reference: it is a practical pharmacology tool for connecting dopamine receptor signaling, antiemetic models, and translational assay design. This article pairs chlorpromazine hydrochloride workflows with new evidence on PEGylated iron oxide nanoparticle interactions in the liver, while clearly separating established mechanisms from hypothesis-generating opportunities.

• PEGylated Iron Oxide Nanoparticles in the Liver

  2026-09-10

  This ACS Nano study systematically separates the effects of iron oxide nanoparticle size and PEG chain length on hepatic distribution and uptake by primary liver cell types. Its central finding—that hepatocytes and hepatic stellate cells can contribute more strongly to uptake than Kupffer cells, while intermediate PEG length may minimize liver accumulation—provides a more nuanced framework for nanomedicine design.

• SCH772984: ERK1/2 Control in NPC Models

  2026-09-10

  SCH772984 is a selective ERK1/2 inhibitor for testing MAPK dependence in cancer models. This article connects its pharmacology with ferroptosis and radioresistance assays while separating evidence-based findings from testable hypotheses in nasopharyngeal carcinoma.

• Cardiogreen: From Vascular Dye to Immune PTT

  2026-09-09

  Cardiogreen (Indocyanine Green) connects vascular imaging, photodynamic therapy, and emerging immune-enabled phototherapy. This translational analysis separates established evidence from testable hypotheses and outlines how researchers can evaluate optical, apoptotic, and macrophage-mediated endpoints.

• 10074-G5 Workflow for c-Myc Cancer Research

  2026-09-09

  10074-G5 provides a practical pharmacological probe for disrupting c-Myc/Max dimerization, connecting pathway biology with apoptosis, cell-cycle, and motility assays. This workflow shows how to translate c-Myc findings from lymphoma models into biomarker-guided esophageal adenocarcinoma experiments while controlling for solubility, exposure, and model-specific responses.

• Ouabain: A Precision Probe for Cardiovascular Translation

  2026-09-09

  Ouabain is more than a classic cardiac glycoside: it is a selective Na+/K+-ATPase inhibitor that can convert ion transport into a tractable translational research variable. This article connects pump inhibition with calcium handling, microvascular physiology, and cardiovascular disease modeling. Building on recent evidence that endothelium-dependent hyperpolarization protects intestinal perfusion during colitis, it outlines how Ouabain can help researchers test whether Na+/K+-ATPase activity shapes vascular resilience, astrocyte calcium storage, and outcomes in heart failure animal models.

• Benzyl-activated Streptavidin Magnetic Beads for HBV Assays

  2026-09-08

  Build cleaner HBV entry and protein-interaction workflows with high-affinity biotin capture, rapid magnetic separation, and adaptable wash conditions. The same platform also supports purification, immunoprecipitation, screening, and nucleic-acid workflows when assay-specific controls are applied.

• Recombinant Annexin V for Apoptosis Detection

  2026-09-07

  Brumatti, Sheridan, and Martin present a practical bacterial-expression workflow for producing soluble polyhistidine-tagged annexin V, purifying it by nickel affinity chromatography, and labeling it with FITC. The method converts phosphatidylserine externalization into a rapid flow-cytometry or fluorescence-microscopy readout while emphasizing calcium dependence and the need to distinguish apoptosis from other forms of membrane injury.

• Vemurafenib: A Causal Lens on Melanoma Resistance

  2026-09-07

  Vemurafenib and PLX4032 provide a precise pharmacological lens for studying BRAF-driven melanoma biology. This article translates multi-omics resistance findings into practical, time-resolved assay strategies for proliferation, signaling, and xenograft research.

• ω-Agatoxin IVA TFA: From Cav2.1 to Translation

  2026-09-05

  A mechanistic and translational guide to using ω-Agatoxin IVA TFA as a selective Cav2.1 probe in neuronal calcium current recording, synaptic transmission research, and epilepsy models.

• TiO2 Sonodynamic Therapy for PCO and Ferroptosis

  2026-09-04

  Li and colleagues developed TiO2 nanoparticle-coated intraocular lenses activated by ultrasound to reduce posterior capsular opacification (PCO). Their cellular, molecular, transcriptomic, and rabbit-eye data indicate that reactive oxygen species, glutathione depletion, GPX4 reduction, and lipid peroxidation contribute to a ferroptosis-like mechanism.

• Bay 11-7821 Workflows for NF-κB Research

  2026-09-04

  Bay 11-7821, also known as BAY 11-7082, provides a practical chemical perturbation point for NF-κB, inflammatory signaling, apoptosis, and macrophage–T-cell studies. This guide connects reporter assays and tumor-cell workflows with the abscopal-effect findings of recent radiotherapy–immunotherapy research, while emphasizing controls and interpretation limits.

• Cytochalasin D for Corneal Nanoparticle Uptake

  2026-09-03

  Cytochalasin D helps separate actin-dependent nanoparticle internalization from simple particle association in human corneal epithelial cell assays. This workflow combines controlled cytoskeletal perturbation with particle-size and surface-chemistry comparisons for more interpretable ocular drug-delivery data.

• Influenza Hemagglutinin (HA) Peptide in Translation

  2026-09-03

  Translational biology depends on experimental systems that preserve mechanistic resolution while supporting reproducible protein analysis. This article connects the IDH1-R132H autopalmitoylation study with strategic HA-tag workflows, showing how a competitive elution reagent can strengthen construct validation, protein-interaction studies, and preclinical evidence chains.

• Maternal IL-17A and Neonatal GBS Risk

  2026-09-02

  A prospective mother–newborn study in Morocco links reduced maternal IL-17A, IL-1β, and IL-4 responses among GBS-colonized women with invasive neonatal GBS disease. Its paired clinical and ex vivo design positions IL-17A as a promising risk-stratification biomarker while highlighting TLR1/2-responsive immune function as a relevant experimental endpoint.

8582 records 1/573 page Next 12345 下5页 Last page